NO20011437L - Öyedråper for å fremme lakrimal sekresjon eller for å behandle keratokonjunktive forstyrrelser som inneholdernatriuretisk peptid som aktiv ingrediens - Google Patents

Öyedråper for å fremme lakrimal sekresjon eller for å behandle keratokonjunktive forstyrrelser som inneholdernatriuretisk peptid som aktiv ingrediens

Info

Publication number
NO20011437L
NO20011437L NO20011437A NO20011437A NO20011437L NO 20011437 L NO20011437 L NO 20011437L NO 20011437 A NO20011437 A NO 20011437A NO 20011437 A NO20011437 A NO 20011437A NO 20011437 L NO20011437 L NO 20011437L
Authority
NO
Norway
Prior art keywords
treat
active ingredient
eye drops
natriuretic peptide
lacrimal secretion
Prior art date
Application number
NO20011437A
Other languages
English (en)
Other versions
NO20011437D0 (no
Inventor
Katsuhiko Nakata
Masatsugu Nakamura
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of NO20011437D0 publication Critical patent/NO20011437D0/no
Publication of NO20011437L publication Critical patent/NO20011437L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
NO20011437A 1998-09-28 2001-03-21 Öyedråper for å fremme lakrimal sekresjon eller for å behandle keratokonjunktive forstyrrelser som inneholdernatriuretisk peptid som aktiv ingrediens NO20011437L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27333298 1998-09-28
PCT/JP1999/005239 WO2000018422A1 (fr) 1998-09-28 1999-09-24 Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite

Publications (2)

Publication Number Publication Date
NO20011437D0 NO20011437D0 (no) 2001-03-21
NO20011437L true NO20011437L (no) 2001-03-21

Family

ID=17526421

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011437A NO20011437L (no) 1998-09-28 2001-03-21 Öyedråper for å fremme lakrimal sekresjon eller for å behandle keratokonjunktive forstyrrelser som inneholdernatriuretisk peptid som aktiv ingrediens

Country Status (7)

Country Link
US (1) US6833358B1 (no)
EP (1) EP1118329A4 (no)
KR (1) KR100691545B1 (no)
CN (1) CN1169573C (no)
CA (1) CA2345414A1 (no)
NO (1) NO20011437L (no)
WO (1) WO2000018422A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2403533A (en) 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
DK2001518T3 (da) 2006-03-30 2013-10-07 Palatin Technologies Inc Cykliske natriuretiske peptidfremstillinger
WO2008137496A1 (en) * 2007-05-04 2008-11-13 Bausch & Lomb Incorporated Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
CN101754745A (zh) * 2007-05-07 2010-06-23 博士伦公司 用于缓解、改善、治疗或预防干眼症的组合物及其制备和使用方法
US20120208756A1 (en) 2009-07-23 2012-08-16 Igisu Co., Ltd Composition for external preparation for skin
RU2502519C2 (ru) 2009-08-27 2013-12-27 Кёко ЭНДО Терапевтическое средство для лечения ринита
RU2636738C2 (ru) 2009-09-25 2017-11-28 Шайр Орфан Терапис ГмбХ Новые агонисты npr-b
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN101947307B (zh) * 2010-08-19 2012-08-15 中山大学中山眼科中心 人胎盘肽在制备治疗干眼症等眼表疾病药物中的应用
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US20130244937A1 (en) 2011-09-02 2013-09-19 Nile Therapeutics, Inc. Chimeric natriuretic peptide compositions and methods of preparation
WO2013127834A1 (en) 2012-02-28 2013-09-06 Ge Healthcare As Vial with free float valve for sterile pharmaceutical
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
AU2017205273C1 (en) 2016-01-08 2022-12-01 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
SG11201805026SA (en) 2016-01-08 2018-07-30 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr-c binding
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
PL3400019T3 (pl) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
CN109843295B (zh) 2016-09-29 2022-04-05 阿森迪斯药物生长障碍股份有限公司 控释cnp激动剂的组合疗法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452818A (en) * 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
JPS60136596A (ja) * 1983-12-26 1985-07-20 Suntory Ltd ペプチド及びこれを有効成分とする利尿剤
ES2076981T5 (es) * 1989-03-01 2000-02-01 Shionogi & Co Polipeptido fisiologicamente activo y su adn.
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
JP2930380B2 (ja) * 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
AU6360394A (en) * 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
JPH10500969A (ja) * 1994-06-02 1998-01-27 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング カルジオジラチンフラグメントの調製方法、高度に精製されたカルジオジラチンフラグメント及びそれらの調製のための中間生成物類
JPH10218792A (ja) * 1997-02-12 1998-08-18 Santen Pharmaceut Co Ltd アンギオテンシン変換酵素阻害薬を有効成分とする涙液分泌促進および角結膜障害治療剤
JPH10236972A (ja) * 1997-02-28 1998-09-08 Mitsubishi Chem Corp 涙液分泌促進剤

Also Published As

Publication number Publication date
WO2000018422A1 (fr) 2000-04-06
EP1118329A1 (en) 2001-07-25
CN1169573C (zh) 2004-10-06
CN1320040A (zh) 2001-10-31
KR20010073181A (ko) 2001-07-31
US6833358B1 (en) 2004-12-21
NO20011437D0 (no) 2001-03-21
EP1118329A4 (en) 2004-12-15
CA2345414A1 (en) 2000-04-06
KR100691545B1 (ko) 2007-03-09

Similar Documents

Publication Publication Date Title
NO20011437L (no) Öyedråper for å fremme lakrimal sekresjon eller for å behandle keratokonjunktive forstyrrelser som inneholdernatriuretisk peptid som aktiv ingrediens
CA2261760A1 (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin
TW200735897A (en) HFSH aqueous formulation
BG105643A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds
WO2002048183A3 (en) Compositions of peptide crystals
LU92780I2 (fr) Trastuzumab et hyaluronidase humaine recombinante
YU83502A (sh) Nova farmaceutska smeša
HUP0300833A3 (en) Gabapentin analogues for treating sleep disorders
NO20043663L (no) Bicykliske aminosyrer som farmasoytiske midler
ATE344027T1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
DK0872247T3 (da) Topisk formulering indeholdende phosphatbuffer som hudgennemtrængningsfremmer
IL150311A0 (en) Sulfonamides and derivatives thereof that modulate the activity of endothelin
DE69818026D1 (de) Wässrige suspension zur nasalen verabreichung von loteprednol
ATE497390T1 (de) Neue therapeutische verwendung von smr-1 peptide
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension.
WO2000009103A3 (en) N-linked sulfonamides of n-heterocyclic carboxylic acids or isosteres for vision and memory disorders
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
HK1112738A1 (en) Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders
FI883643A (fi) Cyklopeptider som befraemjar absorption under anvaendning pao slemhinnorna.
DK0973505T3 (da) Vandigt farmaceutisk præparat, der omfatter en aktiv ingrediens, som er meget tungt opløselig i vand
HUP0400541A3 (en) Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2
WO2002018323A3 (en) Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
NO20032035L (no) Terapeutiske midler for keratokonjuktivitis sykdommer omfattende farnesyleddiksyre som aktiv ingrediens

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application